Drug Profile
Research programme: ZSCAN4 gene therapy - Elixirgen
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Elixirgen
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Congenital heart defects; Down syndrome; Liver cirrhosis; Muscular dystrophies
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Alzheimer's-disease in USA (IV)
- 28 Jan 2024 No recent reports of development identified for research development in Congenital-heart-defects in USA (IV)
- 28 Jan 2024 No recent reports of development identified for research development in Liver-Cirrhosis in USA (IV)